Skip to main content
. 2018 Feb 20;20(2):356–365. doi: 10.1111/jch.13183

Table 1.

Baseline demographics in the full analysis set

Full analysis set eGFR < 60 mL/min/1.73 m2 Patients with diabetes
Olmesartan (n = 2374) Active control (n = 2113) Olmesartan (n = 578) Active control (n = 387) Olmesartan (n = 399) Active control (n = 362)
Age, y 68.3 ± 5.0 68.0 ± 5.0 69.3 ± 5.1 68.9 ± 4.9 68.9 ± 5.0 68.4 ± 4.9
Body mass index, kg/m2 27.7 ± 4.3 27.8 ± 4.2 28.3 ± 4.5 28.2 ± 4.7 28.7 ± 4.5 28.6 ± 4.3
Sex, n (%)
Male 1217 (51.3) 1124 (53.2) 230 (39.8) 146 (37.7) 227 (56.9) 208 (57.5)
Female 1157 (48.7) 989 (46.8) 348 (60.2) 241 (62.3) 172 (43.1) 154 (42.5)
Race, n (%)
Asian 227 (9.6) 216 (10.2) 17 (2.9) 13 (3.4) 31 (7.8) 31 (8.6)
Black or African American 60 (2.5) 78 (3.7) 22 (3.8) 19 (4.9) 16 (4.0) 20 (5.5)
Hispanic or Latino 24 (1.0) 41 (1.9) 0 (0.0) 1 (0.3) 2 (0.5) 4 (1.1)
White 2061 (86.8) 1777 (84.1) 539 (93.3) 354 (91.5) 349 (87.5) 307 (84.8)
Other 2 (0.1) 1 (<0.1) 0 (0.0) 0 (0.0) 1 (0.3) 0 (0.0)
SeSBP, mm Hg 162.9 ± 13.0 162.5 ± 13.1 164.1 ± 13.3 163.4 ± 13.9 163.3 ± 13.1 163.1 ± 13.4
SeDBP, mm Hg 96.9 ± 8.4 97.2 ± 8.2 95.9 ± 9.0 96.9 ± 8.7 95.2 ± 9.3 95.2 ± 8.4
Diabetes, n (%) 401 (16.9) 362 (17.1) 114 (19.7) 75 (19.4) 399 (100.0) 362 (100.0)
eGFR, n (%)
>90 mL/min/1.73 m2 456 (19.2) 489 (23.1) 0 (0.0) 0 (0.0) 77 (19.3) 74 (20.4)
>60 to ≤90 mL/min/1.73 m2 1319 (55.6) 1213 (57.4) 0 (0.0) 0 (0.0) 204 (51.1) 208 (57.5)
>45 to ≤60 mL/min/1.73 m2 489 (20.6) 340 (16.1) 488 (84.4) 334 (86.3) 93 (23.3) 65 (18.0)
>30 to ≤45 mL/min/1.73 m2 75 (3.2) 50 (2.4) 75 (13.0) 50 (12.9) 19 (4.8) 11 (3.0)
>15 to ≤30 mL/min/1.73 m2 15 (0.6) 3 (0.1) 15 (2.6) 3 (0.8) 2 (0.5) 0 (0.0)
Missing data 20 (0.8) 18 (0.9) 0 (0.0) 0 (0.0) 4 (1.0) 4 (1.1)

eGFR, estimated glomerular filtration rate; SeDBP, seated diastolic blood pressure; SeSBP, seated systolic blood pressure.

Data are shown as mean ± standard deviation unless otherwise stated.